TAFI activity and antigen plasma levels are not increased in acute coronary artery disease patients admitted to a coronary care unit

Thrombosis Research

Volumn 118, Issue 4, 2006, Pages 495-500

  Paola Cellai, Anna ^a   Antonucci, Emilia ^a   Alessandrello Liotta, Agatina ^a   Fedi, Sandra ^a   Marcucci, Rossella ^a   Falciani, Michela ^a   Giglioli, Cristina ^a   Abbate, Rosanna ^a   Prisco, Domenico ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Acute myocardial infarction; Coronary artery disease; Fibrinolysis; Fibrinolysis inhibitor; PAI 1; TAFI; Unstable angina

Indexed keywords

ANTIGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY CARE UNIT; CORRELATION ANALYSIS; FEMALE; HUMAN; MALE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; UNIVARIATE ANALYSIS;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; CARBOXYPEPTIDASE U; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY CARE UNITS; ENZYME ACTIVATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1;

EID: 33747877178     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2005.10.006     Document Type: Article

References (35)

1. Bouma B.N., and Meijers J.C. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). J Thromb Haemost 1 (2003) 1566-1574
2. van Tilburg N.H., Rosendaal F.R., and Bertina R.M. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 95 (2000) 2855-2859
3. Eichinger S., Schonauer V., Weltermann A., Minar E., Bialonczyk C., Hirschl M., et al. Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood 103 (2004) 3773-3776
4. Chetaille P., Alessi M.C., Kouassi D., Morange P.E., and Juhan-Vague I. Plasma TAFI antigen variations in healthy subjects. Thromb Haemost 83 (2000) 902-905
5. Juhan-Vague I., Morange P.E., Aubert H., Henry M., Aillaud M.F., Alessi M.C., et al. Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe. Arterioscler Thromb Vasc Biol 22 (2002) 867-873
6. Juhan-Vague I., Renucci J.F., Grimaux M., Morange P.E., Gouvernet J., Gourmelin Y., et al. Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors. Arterioscler Thromb Vasc Biol 20 (2000) 2156-2161
7. Henry M., Aubert H., Morange P.E., Nanni I., Alessi M.C., Tiret L., et al. Identification of polymorphisms in the promoter and the 3′ region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood 97 (2001) 2053-2058
8. Aznar J., Estelles A., Tormo G., Sapena P., Tormo V., Blanch S., et al. Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease. Br Heart J 59 (1988) 535-541
9. Meade T.W., Ruddock V., Stirling Y., Chakrabarti R., and Miller G.J. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 342 (1993) 1076-1079
10. Aznar J., and Estelles A. Role of plasminogen activator inhibitor type 1 in the pathogenesis of coronary artery diseases. Haemostasis 24 (1994) 243-251
11. Thogersen A.M., Jansson J.H., Boman K., Nilsson T.K., Weinehall L., Huhtasaari F., et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 98 (1998) 2241-2247
12. Grancha S., Estelles A., Tormo G., Falco C., Gilabert J., Espana F., et al. Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease. Thromb Haemost 81 (1999) 516-521
13. Capanni M., Antonucci E., Chiarugi L., Boddi V., Abbate R., Prisco D., et al. Impairment of early fibrinolytic activation after PTCA: a mechanism for restenosis-related clinical recurrence?. Fibrinolysis Proteolysis 13 (1999) 8-14
14. Prisco D., Fedi S., Antonucci E., Capanni M., Chiarugi L., Chioccioli M., et al. Postprocedural PAI-1 activity is a risk marker of subsequent clinical restenosis in patients both with and without stent implantation after elective balloon PTCA. Thromb Res 104 (2001) 181-186
15. Silveira A., Schatteman K., Goossens F., Moor E., Scharpe S., Stromqvist M., et al. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost 84 (2000) 364-368
16. Schroeder V., Chatterjee T., Mehta H., Windecker S., Pham T., Devantay N., et al. Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography. Thromb Haemost 88 (2002) 1020-1025
17. Zorio E., Castello R., Falco C., Espana F., Osa A., Almenar L., et al. Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system. Br J Haematol 122 (2003) 958-965
18. Santamaria A., Martinez-Rubio A., Borrell M., Mateo J., Ortin R., and Fontcuberta J. Risk of acute coronary artery disease associated with functional thrombin activatable fibrinolysis inhibitor plasma level. Haematologica 89 (2004) 880-881
19. Newby L.K., Alpert J.S., Ohman E.M., Thygesen K., and Califf R.M. Changing the diagnosis of acute myocardial infarction: implications for practice and clinical investigations. Am Heart J 144 (2002) 957-980
20. Braunwald E., Antman E.M., Beasley J.W., Califf R.M., Cheitlin M.D., Hochman J.S., et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 40 (2002) 1366-1374
21. Cifkova R., Erdine S., Fagard R., Farsang C., Heagerty A.M., Kiowski W., et al. ESH/ESC hypertension guidelines committee. Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens 21 (2003) 1779-1786
22. Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) Final Report. Circulation 106 (2002) 3143-3421
23. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26 (2002) S5-S20
24. Chmielewska J., Ranby M., and Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 31 (1983) 427-436
25. Santamaria A., Borrell M., Oliver A., Ortin R., Forner R., Coll I., et al. Association of functional thrombin-activatable fibrinolysis inhibitor (TAFI) with conventional cardiovascular risk factors and its correlation with other hemostatic factors in a Spanish population. Am J Hematol 76 (2004) 348-352
26. 147Thr polymorphism of the TAFI gene and the angina pectoris incidence. The PRIME study (Prospective Epidemiological Study of MI). Thromb Haemost 89 (2003) 554-560
27. Guimaraes A.H., van Tilburg N.H., Vos H.L., Bertina R.M., and Rijken D.C. Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assays. Br J Haematol 124 (2004) 659-665
28. Mosnier L.O., von dem Borne P.A., Meijers J.C., and Bouma B.N. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 80 (1998) 829-835
29. Montaner J., Ribo M., Monasterio J., Molina C.A., and Alvarez-Sabin J. Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke. Stroke 34 (2003) 1038-1040
30. Santamaria A., Oliver A., Borrell M., Mateo J., Belvis R., Marti-Fabregas J., et al. Risk of ischemic stroke associated with functional thrombin-activatable fibrinolysis inhibitor plasma levels. Stroke 34 (2003) 2387-2391
31. Brouwers G.J., Leebeek F.W., Tanck M.W., Wouter Jukema J., Kluft C., and de Maat M.P. Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris. Thromb Haemost 90 (2003) 92-100
32. Schatteman K.A., Goossens F.J., Scharpe S.S., and Hendriks D.F. Proteolytic activation of purified human procarboxypeptidase U. Clin Chim Acta 292 (2000) 25-40
33. Healy A.M., and Gelehrter T.D. Induction of plasminogen activator inhibitor-1 in HepG2 human hepatoma cells by mediators of the acute phase response. J Biol Chem 269 (1994) 19095-19100
34. Sato T., Miwa T., Akatsu H., Matsukawa N., Obata K., Okada N., et al. Pro-carboxypeptidase R is an acute phase protein in the mouse, whereas carboxypeptidase N is not. J Immunol 16 (2000) 1053-1058
35. Boffa M.B., Hamill J.D., Maret D., Brown D., Scott M.L., Nesheim M.E., et al. Acute phase mediators modulate thrombin-activable fibrinolysis inhibitor (TAFI) gene expression in HepG2 cells. J Biol Chem 278 (2003) 9250-9257